American Association for Cancer Research

SHERPA: Unknown

People

  1. Hudis
    Hudis
  2. Norton
    Norton
  3. Traina
    Traina
  4. Modi
    Modi
  5. Chandarlapaty
    Chandarlapaty
  6. Dang
    Dang
  7. D'Andrea-Carlino
    D'Andrea-Carlino
  8. Gucalp
    Gucalp
  9. Morrow
    Morrow
  10. Lake
    Lake

Groups

  1. Biostatistics Service (69)
  2. Epidemiology and Biostatistics (69)
  3. Department of Medicine (66)
  4. Solid Tumor Oncology Division (66)
  5. Breast Medicine Service (63)
  6. Survivorship Research (61)
  7. Alan and Sandra Gerry Metastasis and Tumor Ecosystems Center (38)
  8. GSK Faculty (28)
  9. Department of Pathology and Laboratory Medicine (24)
  10. Radiology, Department of (24)
Search Within
  1. "Sujata Patil"
Formats
  1. Meeting Abstract (55)
  2. Journal Article (14)
Groups
  1. Biostatistics Service (69)
  2. Epidemiology and Biostatistics (69)
  3. Department of Medicine (66)
  4. Solid Tumor Oncology Division (66)
  5. Breast Medicine Service (63)
  6. Survivorship Research (61)

More Groups

People
  1. Sujata Patil (69)
  2. Clifford Hudis (42)
  3. Larry Norton (31)
  4. Tiffany Traina (19)
  5. Shanu Modi (17)
  6. Maura Dickler (14)

More People

Years
  1. 2022 (2)
  2. 2021 (3)
  3. 2020 (3)
  4. 2019 (7)
  5. 2018 (3)
  6. 2017 (3)

More Years

Publications
  1. Cancer Research (55)
  2. Clinical Cancer Research (14)

Results (69)


Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Associations between pretreatment body composition features and clinical outcomes among patients with metastatic clear cell renal cell carcinoma treated with immune checkpoint blockade
    Journal Article

    Ged, Y.; Sanchez, A.; Patil, S.; Knezevic, A.; Stein, E.; Petruzella, S.; Weiss, K.; Duzgol, C.; Chaim, J.; Akin, O.; more...
    Clinical Cancer Research (2022)

    Fulltext@MSK | Save
  • Adjuvant enzalutamide for the treatment of early-stage androgen-receptor positive, triple negative breast cancer: A feasibility study
    Meeting Abstract

    Walsh, E. M.; Gucalp, A.; Patil, S.; Edelweiss, M.; Ross, D. S.; Razavi, P.; Modi, S.; Iyengar, N. M.; Sanford, R.; Troso-Sandoval, T.; more...
    Cancer Research (2022)

    Fulltext@MSK | Save
  • A phase I study of alpelisib in combination with trastuzumab and LJM716 in patients with PIK3CA-mutated HER2-positive metastatic breast cancer
    Journal Article

    Jhaveri, K.; Drago, J. Z.; Shah, P. D.; Wang, R.; Pareja, F.; Ratzon, F.; Iasonos, A.; Patil, S.; Rosen, N.; Fornier, M. N.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Comprehensive molecular characterization and response to therapy in fumarate hydratase-deficient renal cell carcinoma
    Journal Article

    Gleeson, J. P.; Nikolovski, I.; Dinatale, R.; Zucker, M.; Knezevic, A.; Patil, S.; Ged, Y.; Kotecha, R. R.; Shapnik, N.; Murray, S.; more...
    Clinical Cancer Research (2021)

    Fulltext@MSK | Save
  • Pregnancy-associated breast cancer: Does timing of presentation affect outcome?
    Meeting Abstract

    Crown, A.; McCartan, D.; Curry, M.; Feldman, M.; Patil, S.; Kamer, S.; Goldfarb, S. B.; Gemignani, M.
    Cancer Research (2021)

    Fulltext@MSK | Save
  • Patient-reported outcomes (PROs) during one year of adjuvant enzalutamide for the treatment of early stage androgen receptor positive (AR+) triple negative breast cancer
    Meeting Abstract

    Traina, T. A.; Jones, L. W.; Blinder, V.; Scott, J.; Boyle, L. A.; Arumov, A.; Alano, T.; Patil, S.; DeFusco, P.; Lamparella, N.; more...
    Cancer Research (2020)

    Fulltext@MSK | Save
  • Disease free survival rate with dose dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and pertuzumab (ddACTHP) in patients with HER2-positive early stage breast cancer: A single institution experience
    Meeting Abstract

    Singh, J. C.; Patil, S.; Norton, L.; Robson, M.; Dang, C.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • A randomized phase 2 study of peri-operative ipilimumab, nivolumab and cryoablation versus standard care in women with residual, early stage/resectable, triple negative breast cancer after standard-of-care neoadjuvant chemotherapy
    Meeting Abstract

    McArthur, H.; Comen, E.; Bryce, Y.; Solomon, S. B.; Leal, J.; Rodine, M.; Abaya, C. D.; Patil, S.; Page, D.; Norton, L.
    Cancer Research (2020)

    Fulltext@MSK | Save
  • A pilot randomized usual care controlled study of yoga for persistent chemotherapy-induced peripheral neuropathy (CIPN) in breast and gynecological cancer survivors
    Meeting Abstract

    Zhi, W. I.; Leeolou, M. C.; Piulson, L.; Chen, P.; Patterson, C.; Paul, T.; Patil, S.; Mao, J. J.; Bao, T.
    Cancer Research (2019)

    Fulltext@MSK | Save
  • A randomized phase II study of peri-operative ipilimumab, nivolumab and cryoablation versus standard peri-operative care in women with residual triple negative early stage/resectable breast cancer after standard-of-care neoadjuvant chemotherapy
    Meeting Abstract

    McArthur, H. L.; Comen, E. A.; Solomon, S.; Rodine, M.; DiLauro Abaya, C.; Leal, J. H. S.; Patil, S.; Norton, L.
    Cancer Research (2019)

    Fulltext@MSK | Save

    • American Association for Cancer Research – authorized name for: